Fluorescent in-situ hybridization (FISH) for BCR/ABL in chronic myeloid leukemia after bone marrow transplantation.
BACKGROUND
Identification of Philadelphia chromosome or BCR/ABL gene rearrangement in chronic myeloid leukemia is important at diagnosis as well as after treatment.


OBJECTIVE
To compare the results of karyotyping using fluorescent in-situ hybridization (FISH) upon diagnosis and 1 year after bone marrow transplantation in 12 patients.


METHODS
Diagnostic test and residual disease detection.


METHODS
Hematology and Hemotherapy Department, Federal University of São Paulo/Escola Paulista de Medicina, São Paulo, Brazil.


METHODS
12 patients with chronic myeloid leukemia at diagnosis and 1 year after bone marrow transplantation.


METHODS
Karyotyping was done in the usual way and the BCR/ABL gene-specific probe was used for FISH.


METHODS
Disease at diagnosis and residual.


RESULTS
At diagnosis, 10 patients presented t(9;22)(q34.1;q11) as well as positive FISH. Two cases did not have metaphases but FISH was positive. After bone marrow transplantation, 8 patients presented normal karyotype, 1 had persistence of identifiable Philadelphia chromosome and 3 had no metaphases. Two cases showed complete chimera and 2 had donor and host cells simultaneously. FISH was possible in all cases after bone marrow transplantation and confirmed the persistence of identifiable Philadelphia chromosome clone in one patient, and identified another that did not present metaphases for analysis. Cases that showed mixed chimera in karyotype were negative for BCR/ABL by FISH.


CONCLUSIONS
The applicability of FISH is clear, particularly for residual disease detection. Classical and molecular cytogenetics are complementary methods.
Chauffaille
M de L
Mde L
Discipline of Hematology and Hemotherapy, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil. chauffaill@hemato.epm.br
Oliveira
J S
JS
Romeo
M
M
Kerbauy
J
J
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008297:Male; D018365:Neoplasm, Residual / Q000235:genetics / Q000473:pathology; D010677:Philadelphia Chromosome
D016044:Fusion Proteins, bcr-abl